Return to Publications
RWJBarnabas HealthRutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including clinical trials and novel therapeutics such as precision medicine and immunotherapy.

Return to Publications  |  Return to CINJ Home
Rutgers Cancer Institute of New Jersey's Cancer Connection, April 2016
Donate NowThe latest news on research, treatment, prevention and education from the
state's only National Cancer Institute-designated Comprehensive Cancer Center
Genomic Profiling Helps Provide Targeted Therapy Options for Hard to Treat Cancers



Research from Rutgers Cancer Institute examining difficult to treat cancers through genomic profiling shows tumors with alterations in a signaling pathway responsible for cell regulation may respond to targeted therapy regardless of where the tumor originated. Through a genomic analysis clinical trial at Rutgers Cancer Institute, tumors with the P13K/AKT/mTOR pathway were profiled. Genomic alterations were reviewed by the Institute's molecular tumor board and recommendations for patient treatment options were made. The findings will be presented at the Annual Meeting of the American Association for Cancer Research later this month. Learn more

Intervention for Caregivers of Children Undergoing Stem Cell Transplants Shows Benefit



A social-cognitive intervention designed for parents of children undergoing a stem cell transplant was shown to have beneficial effects in reducing caregiver distress during the hospitalization period as compared with current best-practice psychosocial care. Rutgers Cancer Institute Associate Director for Cancer Prevention, Control and Population Science Sharon Manne, PhD, who is also a professor of medicine at Rutgers Robert Wood Johnson Medical School, is the lead author of the work published in the February 25 issue of Journal of Consulting and Clinical Psychology.Learn more

Elucidating Lung Cancer Risk in African Americans and European Americans



Research from a Rutgers Cancer Institute scientist and colleagues from the National Cancer Institute and other facilities, shows differences in a certain type of small protein that vary by race and may contribute differently to the development of lung cancer in African Americans and European Americans. Rutgers Cancer Institute researcher Sharon R. Pine, PhD, assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, is the co-lead author of the work published in the March 4 issue of Cancer Epidemiology, Biomarkers & Prevention.Learn more

Protecting U.S. Minors from Tanning Bed Exposure



The U.S. Food and Drug Administration recently proposed a number of new restrictions related to the use of tanning beds, including banning their use among individuals younger than 18 years. Rutgers Cancer Institute of New Jersey behavioral scientist Elliot J. Coups, PhD, an associate professor of medicine at Rutgers Robert Wood Johnson Medical School, weighed in on the proposal in the 'Viewpoint' section of the March 16 edition of JAMA Dermatology.Learn more

Rutgers Licenses New Mechanism for Cancer Treatment



BioMotiv, a drug-development accelerator, has created a new biotechnology company, Z53 Therapeutics, to develop new agents for the treatment of p53-dependent cancers using a technology from Rutgers University. The company has licensed intellectual property that shows small molecules can act as zinc metallochaperones to shuttle zinc across cell membranes and reactivate mutant p53. The work originated in the laboratory of Darren Carpizo, MD, PhD, a physician-scientist at Rutgers Cancer Institute and associate professor of surgery and pharmacology at Rutgers Robert Wood Johnson Medical School.Learn more

Director of the New Jersey State Cancer Registry Elected to National Post



Antoinette Stroup, PhD, director of the New Jersey State Cancer Registry and principal investigator of the NCI-SEER Registry at Rutgers Cancer Institute, has been named President-Elect of the North American Association of Central Cancer Registries (NAACCR). She also is an Associate Professor and Chief of the Cancer Epidemiology Division in the Department of Epidemiology at Rutgers School of Public Health. NAACCR is a professional organization that develops and promotes uniform data standards for cancer registration; provides education and training; certifies population-based registries; aggregates and publishes data from central cancer registries; and promotes the use of cancer surveillance data and systems for cancer control and epidemiologic research, public health programs, and patient care to reduce the burden of cancer in North America.

            Rutgers Cancer Institute of New Jersey                                   NCI logo 

Office of Communications         ·        ·        732-235-9871

                        Like us on Facebook                     Join the CINJ Mailing List